Skip to main content
×
Home
    • Aa
    • Aa

Dietary n-3 PUFA and CVD: a review of the evidence

  • Trevor A. Mori (a1)
Abstract

Many clinical and epidemiological studies have shown that the polyunsaturated n-3 fatty acids EPA and DHA from fish and fish oils, provide cardiovascular protection, particularly in the setting of secondary prevention. n-3 Fatty acids beneficially influence a number of cardiometabolic risk factors including blood pressure, cardiac function, vascular reactivity and lipids, as well as having anti-platelet, anti-inflammatory and anti-oxidative actions. They do not appear to adversely interact with other medications such as statins and other lipid-lowering drugs or antihypertensive medications. n-3 Fatty acids have gained widespread usage by general practitioners and clinicians in a number of clinical settings such as pregnancy and infant development, secondary prevention in CHD patients, treatment of dyslipidaemias and haemodialysis patients. Small doses are achievable with consumption of two to three oily fish meals per week or via purified encapsulated preparations now readily available. n-3 Fatty acids, particularly when consumed as fish, should be considered an important component of a healthy diet. The present paper reviews the effects of n-3 fatty acids on cardiometabolic risk factors, concentrating particularly on the evidence from randomised controlled studies in human subjects.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Dietary n-3 PUFA and CVD: a review of the evidence
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Dietary n-3 PUFA and CVD: a review of the evidence
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Dietary n-3 PUFA and CVD: a review of the evidence
      Available formats
      ×
Copyright
Corresponding author
Corresponding author: Professor T. A. Mori, fax 61 8 9224 0246, email trevor.mori@uwa.edu.au
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1. EB Schmidt , H Arnesen , R de Caterina (2005) Marine n-3 polyunsaturated fatty acids and coronary heart disease – Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res 115, 163170.

2. EB Schmidt , H Arnesen , JH Christensen (2005) Marine n-3 polyunsaturated fatty acids and coronary heart disease – Part II: clinical trials and recommendations. Thromb Res 115, 257262.

3. TA Mori & LJ Beilin (2001) Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol 12, 1117.

4. D Mozaffarian & JH Wu (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58, 20472067.

5. LJ Appel , ER Miller , AJ Seidler (1993) Does supplementation of diet with fish-oil reduce blood-pressure – a metaanalysis of controlled clinical-trials. Arch Intern Med 153, 14291438.

6. JM Geleijnse , EJ Giltay , DE Grobbee (2002) Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 20, 14931499.

8. MC Morris , F Sacks & B Rosner (1993) Does fish-oil lower blood-pressure – a metaanalysis of controlled trials. Circulation 88, 523533.

9. GE McVeigh , GM Brennan , JN Cohn (1994) Fish-oil improves arterial compliance in non-insulin-dependent diabetes-mellitus. Arterioscler Thromb 14, 14251429.

11. JP Chin (1994) Marine oils and cardiovascular reactivity. Prostaglandins Leukot Essent Fatty Acids 50, 211222.

12. TA Mori , GF Watts , V Burke (2000) Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 102, 12641269.

13. WS Harris (1996) n-3 Fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids 31, 243252.

15. PC Calder (2001) Polyunsaturated fatty acids, inflammation, and immunity. Lipids 36, 10071024.

17. TA Mori & LJ Beilin (2004) Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 6, 461467.

18. PC Calder (2012) The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res 56, 10731080.

19. CN Serhan & NA Petasis (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111, 59225943.

20. E Mas , RJ Woodman , V Burke (2010) The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: results from two placebo-controlled interventions. Free Radic Res 44, 983990.

21. TA Mori & RJ Woodman (2006) The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. Curr Opin Clin Nutr Metab Care 9, 95104.

23. HC Bucher , P Hengstler , C Schindler (2002) n-3 Polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112, 298304.

24. K He , YQ Song , ML Daviglus (2004) Accumulated evidence on fish consumption and coronary heart disease mortality – A meta-analysis of cohort studies. Circulation 109, 27052711.

25. SP Whelton , J He , PK Whelton (2004) Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol 93, 11191123.

26. EB Levitan , A Wolk & MA Mittleman (2009) Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. Eur Heart J 30, 14951500.

27. D Mozaffarian , CL Bryson , RN Lemaitre (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45, 20152021.

28. K He , YQ Song , ML Daviglus (2004) Fish consumption and incidence of stroke – A meta-analysis of cohort studies. Stroke 35, 15381542.

29. P Xun , B Qin , Y Song (2012) Fish consumption and risk of stroke and its subtypes: accumulative evidence from a meta-analysis of prospective cohort studies. Eur J Clin Nutr 66, 11991207.

33. M Yokoyama , H Origasa , M Matsuzaki (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis. Lancet 369, 10901098.

35. D Mozaffarian , R Marchioli , A Macchia (2012) Fish oil and postoperative atrial fibrillation the omega-3 fatty acids for prevention of post-operative atrial fibrillation (OPERA) randomized trial. Jama-J Am Med Assoc 308, 20012011.

37. HO Dickinson , JM Mason , DJ Nicolson (2006) Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 24, 215233.

38. RS Dokholyan , CM Albert , LJ Appel (2004) Trial of omega-3 fatty acids for prevention of hypertension. Am J Cardiol 93, 10411043.

39. L Cobiac , PJ Nestel , LMH Wing (1992) A low-sodium diet supplemented with fish oil lowers blood-pressure in the elderly. J Hypertens 10, 8792.

40. P Singer , S Melzer , M Goschel (1990) Fish oil amplifies the effect of propranolol in mild essential-hypertension. Hypertension 16, 682691.

41. YK Lungershausen , M Abbey , PJ Nestel (1994) Reduction of blood-pressure and plasma triglycerides by omega-3-fatty-acids in treated hypertensives. J Hypertens 12, 10411045.

42. DQ Bao , TA Mori , V Burke (1998) Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension 32, 710717.

43. TA Mori , DQ Bao , V Burke (1999) Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34, 253260.

46. D Mozaffarian , A Geelen , IA Brouwer (2005) Effect of fish oil on heart rate in humans – A meta-analysis of randomized controlled trials. Circulation 112, 19451952.

47. MP Pase , NA Grima & J Sarris (2011) Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Brit J Nutr 106, 974980.

49. JH Christensen & EB Schmidt (2001) n-3 Fatty acids and the risk of sudden cardiac death. Lipids 36, S115S118.

50. W Xin , W Wei & XY Li (2013) Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr 97, 926935.

51. A Leaf , JX Kang , YF Xiao (2003) Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 107, 26462652.

54. WS Harris & D Bulchandani (2006) Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 17, 387393.

55. AJ Cussons , GF Watts , TA Mori (2009) Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 94, 38423848.

56. RJ Woodman , TA Mori , V Burke (2003) Docosahexaenoic acid but not eicosapentaenoic acid increases LDL particle size in treated hypertensive type 2 diabetic patients. Diabetes Care 26, 253.

57. J Hulthe , L Bokemark , J Wikstrand (2000) The metabolic syndrome, LDL particle size, and atherosclerosis – the atherosclerosis and insulin resistance (AIR) study. Arterioscler Throm Vas 20, 21402147.

58. S Lahdenpera , M Syvanne , J Kahri (1996) Regulation of low-density lipoprotein particle sire distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 39, 453461.

59. DC Chan , GF Watts , TA Mori (2002) Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 32, 429436.

60. CE Friedberg , MJFM Janssen , RJ Heine (1998) Fish oil and glycemic control in diabetes – A meta-analysis. Diabetes Care 21, 494500.

61. J Hartweg , R Perera , V Montori (2008) Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Db Syst Rev. Issue 1. Article number CD 003205. doi: 10.1002/14651858.CD003205.pub 2.

62. VM Montori , A Farmer , PC Wollan (2000) Fish oil supplementation in type 2 diabetes – A quantitative systematic review. Diabetes Care 23, 14071415.

63. TA Mori , LJ Beilin , V Burke (1997) Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 17, 279286.

64. SD Kristensen , AMB Iversen & EB Schmidt (2001) n-3 Polyunsaturated fatty acids and coronary thrombosis. Lipids 36, S79S82.

66. G Bannenberg , M Arita & CN Serhan (2007) Endogenous receptor agonists: resolving inflammation. Sci World J 7, 14401462.

67. CN Serhan (2005) Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr Opin Clin Nutr Metab Care 8, 115121.

68. CN Serhan (2005) Novel omega-3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther 105, 721.

69. CN Serhan , SD Brain , CD Buckley (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J 21, 325332.

70. CN Serhan & N Chiang (2013) Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 13, 632640.

71. RR Ji , ZZ Xu , G Strichartz (2011) Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci 34, 599609.

72. CN Serhan , N Chiang & TE Van Dyke (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349361.

73. I Tabas (2010) Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 10, 3646.

74. E Mas , KD Croft , P Zahra (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58, 14761484.

75. F Thies , JMC Garry , P Yaqoob (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477485.

76. TA Mori , DW Dunstan , V Burke (1999) Effect of dietary fish and exercise training on urinary F2-isoprostane excretion in non-insulin-dependent diabetic patients. Metabolism 48, 14021408.

77. TA Mori , RJ Woodman , V Burke (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35, 772781.

78. TA Mori , IB Puddey , V Burke (2000) Effect of omega 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F2-isoprostane excretion. Redox Rep 5, 4546.

79. GL Milne , HY Yin , KD Hardy (2011) Isoprostane Generation and Function. Chem Revi 111, 59735996.

80. AE Barden , TA Mori , JA Dunstan (2004) Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. Free Radic Res 38, 233239.

81. DM Lloyd-Jones , YL Hong , D Labarthe (2010) Defining and setting national goals for cardiovascular health promotion and disease reduction the American heart association's strategic impact goal through 2020 and beyond. Circulation 121, 586613.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Proceedings of the Nutrition Society
  • ISSN: 0029-6651
  • EISSN: 1475-2719
  • URL: /core/journals/proceedings-of-the-nutrition-society
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 28
Total number of PDF views: 117 *
Loading metrics...

Abstract views

Total abstract views: 253 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 23rd May 2017. This data will be updated every 24 hours.